Breaking Now: (AMIX) Taps $2.62—With Approx. 50% Early Move on Patent News

*Sponsored Market Crux Just Announced (AMIX) As Its Next Potential Breakout Idea… And Here’s Why… Analyst Targets Released: (AMIX) Was Recently Assigned A $5 Target By Maxim Group And An $18 Target By Ladenburg Thalmann. Tight Share Structure: (AMIX) Has A Float Under 2M Shares And A Market Cap Below $5M. Recent Market Recognition: (AMIX) Moved Approximately 85% In Less Than A Month—From $1.52 To $2.82 Between April 9 And April 29. Technical Signals: (AMIX) Opened Near Its 5-Day Moving Average While The 100-Day Remains Up At $2.4666. Take A Look At (AMIX) Before The Bell Rings… May 15, 2025 Dear Reader, Are you watching (AMIX) yet? Word is just starting to circulate—(AMIX) has been granted a key U.S. patent for its catheter-based nerve-targeting system, reinforcing its position in the precision-guided treatment space. On the heels of this announcement, (AMIX) tapped $2.62 in the early session—an approximate 50% overnight move that pushed it above its 5-, 20-, 50-, and 100-day moving averages in one clean break. The newly issued U.S. Patent No. 12,257,071 protects critical components of a minimally invasive platform designed to map, monitor, and ablate overactive nerves in real time—supporting next-generation approaches to conditions like chronic pain, hypertension, and other nerve-related disorders. With over 80 patents now issued and 40 more pending, (AMIX) is gaining attention for its expanding IP footprint and momentum in the nerve-focused treatment space. This news is starting to circulate.  If you missed my coverage from last night and earlier this morning, keep reading to get up to speed on why we’re excited to bring you (AMIX) today. It always starts quietly—a low-float name slipping under the radar, showing early signs of movement while most remain focused elsewhere. But momentum doesn’t wait for permission. And when technical signals and analyst coverage collide, things can start to accelerate fast. That’s exactly what’s been unfolding in recent weeks. The company is Autonomix Medical, Inc. (NASDAQ: AMIX)—operating with a float under 2M shares and a market cap currently below $5M.  That kind of structure doesn’t just attract attention—it amplifies what happens when it shows up. Between April 9 and April 29, (AMIX) went from $1.52 to $2.82—an approximate 85% move in under a month.  After cooling off, yesterday it opened at $1.77, trending just above its 5-day moving average of $1.76. The 20- and 50-day moving averages sit at $1.9664 and $1.9457, while the 100-day moving average is still up at $2.4666. Now comes the analyst coverage. Last week, on May 9, Maxim Group’s Anthony Vendett released a report assigning (AMIX) a $5 target—representing more than 180% upside potential from today’s open.  Then, in a new note released just yesterday, Jeffrey Cohen of Ladenburg Thalmann, one of the oldest firms in the country, revealed a $18 target—which suggests over 900% upside potential from (AMIX)’s open yesterday. With this kind of momentum, structure, and coverage lining up, it’s no surprise that more eyes are shifting toward what may be one of the most advanced nerve-targeted treatment platforms in development today. A Platform Designed for Precision… Autonomix has engineered a first-in-class transvascular technology built around one radical idea: to sense, treat, and verify nerve activity—in real time, with real accuracy. Rather than relying on bulky lab equipment or generalized ablation techniques, their system miniaturizes powerful signal processing into a proprietary ASIC-powered microchip—roughly the size of a grain of rice—that sits directly next to the nerve.  The result?   Neural signals less than 5μV can now be detected and acted upon with unprecedented precision. This isn't theoretical.  The system already showed statistically significant pain relief in the company’s first-in-human proof-of-concept trial focused on intractable pain in pancreatic cancer. Let’s break down some of the milestones now drawing attention: Autonomix Medical, Inc. (NASDAQ: AMIX)’s Key Highlights… 120+ Patents in their IP portfolio, covering signal detection, catheter design, and nerve-targeting algorithms. 100% Response Rate in patients treated via femoral access during the PoC 1 trial for pancreatic cancer pain. 59.2% Mean Pain Reduction in responders, with zero opioid use in 73% of patients at the 4-6 week mark. FDA De Novo Submission Target: Autonomix is aiming to file for clearance in 2026. PoC 2 Expansion is set to double the addressable market by expanding to additional visceral cancers, including liver, gallbladder, and bile duct cases. Leadership with Proven Exits: Key members of the Autonomix team were behind medical tech companies that were acquired for $550M and $2.4B, respectively. Recent Headlines… May 13, 2025 CEO Highlights Expansion Study Set to Begin in Q2 2025 Closely tied to the upcoming clinical expansion, this update reinforces the imminent start of PoC 2—expected to potentially double the company’s addressable market. It also demonstrates clear leadership involvement and ongoing clinical progression. May 5, 2025 Patient Testimonial Underscores Rapid Pain Relief in Early Trial A compelling patient video shared by the company offers firsthand insight into the platform’s potential. The testimonial highlights rapid pain relief following nerve-targeted treatment, lending powerful real-world validation to Autonomix’s clinical claims. April 30, 2025 PoC 1 Trial Shows Strong Early Results; PoC 2 Now Underway This pivotal update confirmed that PoC 1 achieved meaningful pain reduction and met all key objectives. More importantly, it marked the official launch of PoC 2—an expansion into additional cancer-related pain applications. This progression underscores both the platform’s validation and its future direction. April 24, 2025 Technology Featured at EuroPCR Interventional Medicine Event Autonomix’s system and clinical data were selected for presentation at EuroPCR, one of the leading global conferences in interventional cardiovascular medicine. This inclusion signals growing peer recognition and credibility within the clinical community. Behind the Scenes… During a recent clinical update, Autonomix described a pivotal moment in their early trials. A lead physician overseeing one of the pancreatic cancer cases shared how pain scores dropped within 24 hours, and how patients returned to functionality that had been unreachable for months.  For a trial built around severely ill individuals, this kind of rapid feedback wasn’t just encouraging—it was telling. Behind closed doors, engineers, clinicians, and software teams are working together to turn this into a repeatable system across broader indications. Their goal: deliver a clear signal—and a clear solution—through the noise of traditional pain treatment. The Next Phase Begins… As of Q2 2025, Autonomix is launching PoC 2, a larger and more ambitious expansion of their technology.  This follow-on trial targets earlier-stage pancreatic cancer patients and introduces new visceral cancer pain targets—placing the technology into use cases with higher potential durability and scale. With a total addressable target spread across multiple therapeutic areas, the company is positioning itself at the crossroads of precision pain therapy and neural diagnostics—a field where tools have often lagged behind the science. Why This Little-Known Company is Gaining Attention… Autonomix isn’t just another medical device company. It’s aiming to become a platform for nerve-targeted medicine, beginning with pain but capable of extending into broader neurological conditions where current tools fall short. With a fully integrated system, clinical results already in hand, and a top-tier team experienced in navigating from prototype to acquisition, it’s easy to see why AMIX is starting to appear on more watchlists. This may be a name to keep in view—especially as new data, trial expansions, and regulatory steps unfold over the coming months. Momentum is already building—but when you look at the structure, the setup, and the timing, it becomes clear why this name is getting harder to ignore. With eyes on tomorrow’s session, here’s what’s standing out right now: 7 Reasons Why (AMIX) Is Topping Our Watchlist This  Morning—Thursday, May 15, 2025… 1. Coverage from Analysts: (AMIX) was recently assigned a $5 target by Maxim Group and an $18 target by Ladenburg Thalmann—two calls that suggest over 180% and 900% upside potential, respectively. 2. Razor Thin Float: (AMIX) has a float under 2M shares and a sub-$5M market cap—conditions that can set the stage for big swing potential should demand begin to shift. 3. Recent Market Recognition: From April 9 to April 29, (AMIX) moved approximately 85%, from $1.52 to $2.82 in less than four weeks. 4. Technical Signals: (AMIX) opened today near its 5-day moving average of $1.76, while the 100-day average is still up at $2.4666—creating a gap that chart-watchers are monitoring closely. 5. Clinically Significant Results: (AMIX) showed a 100% response rate via femoral access in its first trial phase, with 73% of responders reaching zero opioid use at follow-up. 6. Expansion Already Underway: (AMIX) is now entering PoC 2—a broader trial targeting earlier-stage conditions and new visceral cancer indications, potentially doubling its clinical reach. 7. Spotlight in Recent Events: (AMIX) has appeared in global medical forums, featured technology presentations, and released a testimonial video that drew attention to its early success. With technical strength, analyst coverage, and trial momentum now converging, the setup on (AMIX) has moved from under-the-radar to front-and-center. If this isn't on your screen yet, now might be the time to start paying closer attention. Pull Up (AMIX) Before The Bell Rings… With a precision-targeted platform backed by promising early results, consistent coverage from established analysts, and a tightly held share structure, Autonomix Medical, Inc. (NASDAQ: AMIX) is quickly becoming a name that’s difficult to overlook.  The technical setup, combined with recent trial momentum and broader visibility, continues to build interest around what could be a significant advancement in nerve-focused medicine. We have all eyes on (AMIX) this morning. Take a look at (AMIX) before the bell rings. And remember—(AMIX) has less than 2M shares listed in the public float—which could set the stage for big swing potential if demand begins to shift. (AMIX) tapped $2.62 in the early session—an approximate 50% overnight move that pushed it above its 5-, 20-, 50-, and 100-day moving averages in one clean break.  Also—keep an eye out for my next update, it could be out to you at any moment. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. *Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 05/14/2025 and ending on 05/15/2025 to publicly disseminate information about (AMIX:US) via digital communications. Under this agreement, Headline Media LLC has been paid seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Headline Media LLC has been paid sixteen thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Headline Media LLC, TD Media LLC and their member own shares of (AMIX:US). Please see important disclosure information here: https://marketcrux.com/disclosure/amix-8hAJD/#details

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice